JP2022507103A5 - - Google Patents

Info

Publication number
JP2022507103A5
JP2022507103A5 JP2021525303A JP2021525303A JP2022507103A5 JP 2022507103 A5 JP2022507103 A5 JP 2022507103A5 JP 2021525303 A JP2021525303 A JP 2021525303A JP 2021525303 A JP2021525303 A JP 2021525303A JP 2022507103 A5 JP2022507103 A5 JP 2022507103A5
Authority
JP
Japan
Prior art keywords
corticosteroid
dose
hsd1 inhibitor
urinary
composition
Prior art date
Application number
JP2021525303A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2020106337A5 (https=
JP2022507103A (ja
JP7472122B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/046449 external-priority patent/WO2020106337A1/en
Publication of JP2022507103A publication Critical patent/JP2022507103A/ja
Publication of JP2022507103A5 publication Critical patent/JP2022507103A5/ja
Publication of JPWO2020106337A5 publication Critical patent/JPWO2020106337A5/ja
Priority to JP2024063590A priority Critical patent/JP2024098991A/ja
Application granted granted Critical
Publication of JP7472122B2 publication Critical patent/JP7472122B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021525303A 2018-11-20 2019-08-14 コルチコステロイドを投与する方法 Active JP7472122B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024063590A JP2024098991A (ja) 2018-11-20 2024-04-10 コルチコステロイドを投与する方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862769932P 2018-11-20 2018-11-20
US62/769,932 2018-11-20
PCT/US2019/046449 WO2020106337A1 (en) 2018-11-20 2019-08-14 Methods for administering corticosteroids

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024063590A Division JP2024098991A (ja) 2018-11-20 2024-04-10 コルチコステロイドを投与する方法

Publications (4)

Publication Number Publication Date
JP2022507103A JP2022507103A (ja) 2022-01-18
JP2022507103A5 true JP2022507103A5 (https=) 2022-08-23
JPWO2020106337A5 JPWO2020106337A5 (https=) 2022-08-23
JP7472122B2 JP7472122B2 (ja) 2024-04-22

Family

ID=70774135

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021525303A Active JP7472122B2 (ja) 2018-11-20 2019-08-14 コルチコステロイドを投与する方法
JP2024063590A Pending JP2024098991A (ja) 2018-11-20 2024-04-10 コルチコステロイドを投与する方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024063590A Pending JP2024098991A (ja) 2018-11-20 2024-04-10 コルチコステロイドを投与する方法

Country Status (10)

Country Link
US (2) US12220412B2 (https=)
EP (1) EP3883578A4 (https=)
JP (2) JP7472122B2 (https=)
CN (1) CN113329754A (https=)
AU (2) AU2019384074B2 (https=)
BR (1) BR112021009653A2 (https=)
CA (1) CA3120339A1 (https=)
IL (2) IL283069B2 (https=)
MX (2) MX2021005801A (https=)
WO (1) WO2020106337A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022076398A1 (en) * 2020-10-07 2022-04-14 Surface Ophthalmics, Inc. Pharmaceutical kits and their use for treating dry eye disease
CN113329754A (zh) 2018-11-20 2021-08-31 麻雀制药股份有限公司 用于施用皮质类固醇的方法
CA3124945A1 (en) 2018-12-27 2020-07-02 Surface Ophthalmics, Inc. Ophthalmic pharmaceutical compositions and methods for treating ocular surface disease
BR112021015481A2 (pt) * 2019-02-08 2021-12-07 Sanofi Sa Otimização biotecnológica de micro-organismos para a 1,2-desidrogenação de esteroides
US12440510B2 (en) 2021-05-10 2025-10-14 Surface Ophthalmics, Inc. Use of chondroitin sulfate for relieving ocular pain
US12310981B2 (en) 2021-05-10 2025-05-27 Surface Ophthalmics, Inc. Use of chondroitin sulfate for relieving ocular pain
WO2023225507A1 (en) * 2022-05-16 2023-11-23 Sparrow Pharmaceuticals, Inc. Methods and compositions for treating glucocorticoid excess
EP4525983A4 (en) * 2022-05-16 2025-09-03 Sparrow Pharmaceuticals Inc METHODS AND COMPOSITIONS FOR TREATING GLUCOCORTICOID EXCESS
AU2024348222A1 (en) * 2023-09-27 2026-04-16 Sparrow Pharmaceuticals, Inc. Methods and compositions for treating glucocorticoid-mediated diseases
GB202408335D0 (en) 2024-06-11 2024-07-24 Astrazeneca Ab Therapies for wound treatment

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3907821A (en) 1974-11-20 1975-09-23 Upjohn Co 2-{8 3-{8 1-(DIMETHYLAMINO)CYCLOPROPYL{8 -4H-1,2,4-triazol-4-yl{8 {0 benzophenone
US4577020A (en) 1983-01-25 1986-03-18 The Upjohn Company Aminoalkyl and aminoalkenyl triazoles as anti-psychotic agents
IL84093A (en) 1986-10-09 1992-09-06 Ciba Geigy Ag Aralkyl-4h-1,2,4-triazole derivatives,their preparation and pharmaceutical compositions containing them
GB0101447D0 (en) * 2001-01-19 2001-03-07 Univ Edinburgh Regulation of glucocorticoid concentration
GB0107383D0 (en) 2001-03-23 2001-05-16 Univ Edinburgh Lipid profile modulation
AUPR878201A0 (en) 2001-11-09 2001-12-06 Fujisawa Pharmaceutical Co., Ltd. New compounds
WO2003059267A2 (en) 2001-12-21 2003-07-24 Rhode Island Hospital SELECTIVE 11β-HSD INHIBITORS AND METHODS FOR USE THEREOF
WO2003065983A2 (en) 2002-02-01 2003-08-14 Merck & Co., Inc. 11-beta-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia
AR040241A1 (es) 2002-06-10 2005-03-23 Merck & Co Inc Inhibidores de la 11-beta-hidroxiesteroide deshidrogrenasa 1 para el tratamiento de la diabetes obesidad y dislipidemia
IL166510A0 (en) 2002-08-09 2006-01-15 Nps Pharma Inc 1,2,4"oxadiazole as modulators of metabotropic glutamate receptor-5
JO2397B1 (en) 2002-12-20 2007-06-17 ميرك شارب اند دوم كوربوريشن Terazol derivatives as beta-hydroxy steroid dihydrogenase-1 inhibitors
ATE467616T1 (de) 2003-04-11 2010-05-15 High Point Pharmaceuticals Llc Verbindungen mit aktivität an der 11beta- hydroxasteroiddehydrogenase
US20060094699A1 (en) * 2003-04-11 2006-05-04 Kampen Gita Camilla T Combination therapy using an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor and a glucocorticoid receptor agonist to minimize the side effects associated with glucocorticoid receptor agonist therapy
WO2004089367A1 (en) 2003-04-11 2004-10-21 Novo Nordisk A/S Pharmaceutical use of substituted 1,2,4-triazoles
DE602004025220D1 (de) 2003-04-11 2010-03-11 High Point Pharmaceuticals Llc Pharmazeutische verwendungen von kondensierten 1,2,4-triazolen
US8026264B2 (en) 2003-05-29 2011-09-27 Merck Sharp And Dohme Corp. Triazole derivatives as inhibitors of 11-β hydroxysteroid dehydrogenase-1
AU2004286836A1 (en) 2003-10-28 2005-05-19 Amgen Inc. Triazole compounds and uses related thereto
JP2005170939A (ja) 2003-11-20 2005-06-30 Takeda Chem Ind Ltd 糖尿病の予防・治療剤
AP2006003633A0 (en) 2003-12-19 2006-06-30 Pfizer Benzenesulfonylamino-pyridin-2-yl derivatives and related compounds as inhibitors of 11-BETA-hydroxysteroid dehydrogenase type 1 (11-BETA-HSD-1) for the treatment of diabetes and obesity
US7507832B2 (en) 2003-12-22 2009-03-24 Eli Lilly And Company Triazole PPAR modulators
AU2005230864A1 (en) 2004-03-29 2005-10-20 Merck Sharp & Dohme Corp. Diaryltriazoles as inhibitors of 11-beta-hydroxysteroid dehydrogenase-1
US8415354B2 (en) 2004-04-29 2013-04-09 Abbott Laboratories Methods of use of inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme
US7880001B2 (en) 2004-04-29 2011-02-01 Abbott Laboratories Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme
US8022225B2 (en) 2004-08-04 2011-09-20 Taisho Pharmaceutical Co., Ltd Triazole derivative
JP4882748B2 (ja) 2004-09-16 2012-02-22 アステラス製薬株式会社 トリアゾール誘導体またはその塩
JP2008518903A (ja) 2004-11-02 2008-06-05 ファイザー・インク 置換および非置換アダマンチルアミドの新規化合物
WO2006068199A1 (ja) 2004-12-22 2006-06-29 Mochida Pharmaceutical Co., Ltd. 代謝的に安定な３－オキシ－１，２，４－トリアゾール誘導体
WO2006080533A1 (ja) 2005-01-31 2006-08-03 Mochida Pharmaceutical Co., Ltd. ３－アミノ－１,２,４－トリアゾール誘導体
WO2006134481A1 (en) 2005-06-16 2006-12-21 Pfizer Inc. Inhibitors of 11-beta hydroxysteroid dehydrogenase type 1
CN101198605A (zh) 2005-06-16 2008-06-11 辉瑞大药厂 N-(吡啶-2-基)-磺酰胺衍生物
AU2006257646A1 (en) 2005-06-16 2006-12-21 Pfizer Inc. N-(pyridin-2-YL)-sulfonamide derivatives
WO2007007688A1 (ja) 2005-07-08 2007-01-18 Mochida Pharmaceutical Co., Ltd. ３,５－ジアミノ－１,２,４－トリアゾール誘導体
JP5261176B2 (ja) 2005-08-16 2013-08-14 アイカジェン， インコーポレイテッド 電位作動型ナトリウムチャンネル阻害剤
AR058807A1 (es) 2005-09-29 2008-02-27 Astrazeneca Ab 5-(fenilisoxazoletoxi)-triazol-3-il piridinas sustituidas, para el tratamiento de trastornos mediados por el receptor mglur5
BRPI0708782A2 (pt) 2006-03-16 2011-06-14 Astellas Pharma Inc derivado de triazol ou um sal deste
US20070224298A1 (en) 2006-03-23 2007-09-27 Talbott Shawn M Inhibiting 11(beta)-hsd1 with citrus flavonoids
US7435833B2 (en) 2006-04-07 2008-10-14 Abbott Laboratories Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme
WO2010001946A1 (ja) 2008-07-03 2010-01-07 アステラス製薬株式会社 トリアゾール誘導体またはその塩
EP2243494A1 (en) * 2009-04-22 2010-10-27 OntoChem GmbH Pharmaceutical composition, comprising a steroid-dehydrogenase-reductase inhibitor, and a mineralocorticoid receptor antagonist.
WO2011068927A2 (en) * 2009-12-04 2011-06-09 Abbott Laboratories 11-β-HYDROXYSTEROID DEHYDROGENASE TYPE 1 (11B-HSD1) INHIBITORS AND USES THEREOF
GB201003734D0 (en) * 2010-03-05 2010-04-21 Univ Strathclyde Delayed prolonged drug delivery
UA112418C2 (uk) * 2010-09-07 2016-09-12 Астеллас Фарма Інк. Терапевтичний болезаспокійливий засіб
SG11201405214YA (en) * 2012-03-13 2014-10-30 Abbvie Inc Method for selecting or identifying a subject for v1b antagonist therapy
CN106659723A (zh) * 2014-07-09 2017-05-10 爱普制药有限责任公司 用于治疗神经病症的方法
US10894054B2 (en) 2015-04-07 2021-01-19 Intercept Pharmaceuticals, Inc. FXR agonist compositions for combination therapy
US10648506B2 (en) 2016-07-07 2020-05-12 Raul Mendoza Walking rig creeper interface
WO2018117063A1 (ja) 2016-12-20 2018-06-28 アステラス製薬株式会社 焦燥性興奮治療剤
CN113329754A (zh) 2018-11-20 2021-08-31 麻雀制药股份有限公司 用于施用皮质类固醇的方法
EP3821892A1 (en) 2019-11-12 2021-05-19 University of Leeds (s)-2-(1-(5-(cyclohexylcarbamoyl)-6-(propylthio)pyridin-2-yl)piperidin-3-yl) acetic acid for use in treating wounds
EP3878446A1 (en) 2020-03-09 2021-09-15 Universite De Geneve Hsd11b1 inhibitors for use in immunotherapy and uses thereof
EP4525983A4 (en) 2022-05-16 2025-09-03 Sparrow Pharmaceuticals Inc METHODS AND COMPOSITIONS FOR TREATING GLUCOCORTICOID EXCESS
WO2023225507A1 (en) 2022-05-16 2023-11-23 Sparrow Pharmaceuticals, Inc. Methods and compositions for treating glucocorticoid excess

Similar Documents

Publication Publication Date Title
JP2022507103A5 (https=)
US20250205227A1 (en) Methods for administering corticosteroids
Hilderson et al. Treatment of renal sarcoidosis: is there a guideline? Overview of the different treatment options
Seo Perioperative glucocorticoid management based on current evidence
JP2020520889A5 (https=)
BR112012019725A2 (pt) usos de uma composição farmacêutica e uso de pelo menos um progestogênio
JP2013518908A5 (https=)
JPWO2020106337A5 (https=)
WO2008087437A1 (en) Treatment of corticoid-resistant asthma or copd with p38 map kinase inhibit (eg. sb2035809)
US20120245552A1 (en) Combination Therapy
RU2021113995A (ru) Способы введения кортикостероидов
US20120309722A1 (en) Therapeutic regimens for the treatment of immunoinflammatory disorders
JP7033454B2 (ja) Ａｅｒｄ／喘息におけるトロンボキサン受容体拮抗薬
Babaoğlu et al. Therapeutic mechanisms of glucocorticoids, their administration and chronotherapy
Papi et al. Fluticasone propionate/formoterol: A fixed-combination therapy with flexible dosage
Bissell et al. Glucocorticoids
TW201726145A (zh) 用於維持皮質類固醇滑液濃度之皮質類固醇調配物
Deepalakshmi et al. A Comprehensive Review on Corticosteroids
Anandabaskar Adrenocorticosteroids and Their Antagonists
JPWO2022061303A5 (https=)
US3231468A (en) Dexamethasone-cyproheptadine oral antiflammatory compositions
US20070259841A1 (en) Combinations for the treatment of rheumatoid arthritis
Call Treatment of Adrenocorticosteroid Disorders
Fluticasone 21 CH2OH CH2OH CH2OH
JPWO2023183807A5 (https=)